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ABSTRACT
Objective: To demonstrate the importance of considering all relevant indi-
rect data in a network meta-analysis of treatments for non–small-cell lung
cancer (NSCLC).
Methods: A recent National Institute for Health and Clinical Excellence
appraisal focussed on the indirect comparison of docetaxel with erlotinib
in second-line treatment of NSCLC based on trials including a common
comparator. We compared the results of this analysis to a network meta-
analysis including other trials that formed a network of evidence. We also
examined the importance of allowing for the correlations between the
estimated treatment effects that can arise when analysing such networks.
Results: The analysis of the restricted network including only trials of
docetaxel and erlotinib linked via the common placebo comparator pro-
duced an estimated mean hazard ratio (HR) for erlotinib compared with
docetaxel of 1.55 (95% conﬁdence interval [CI] 0.72–2.97). In contrast,
the network meta-analysis produced an estimated HR for erlotinib com-
pared with docetaxel of 0.83 (95% CI 0.65–1.06). Analyzing the wider
network improved the precision of estimated treatment effects, altered
their rankings and also allowed further treatments to be compared. Some
of the estimated treatment effects from the wider network were highly
correlated.
Conclusions: This empirical example shows the importance of consider-
ing all potentially relevant data when comparing treatments. Care should
therefore be taken to consider all relevant information, including correla-
tions induced by the network of trial data, when comparing treatments.
Keywords: indirect comparison, mixed treatment comparisons, network
meta-analysis, non–small-cell lung cancer.
Introduction
A recent National Institute for Health and Clinical Excellence
(NICE) review of second-line treatments for stage III/IV non–
small-cell lung cancer (NSCLC) [1] focused on a comparison of
the overall survival associated with erlotinib and docetaxel. As
there were no trials directly comparing both treatments, an indi-
rect comparison was performed based on trials including the
common comparator of placebo. We compare this analysis with
network meta-analysis utilising evidence from a wider network
of clinical trials. This allows us to address the decision problem
posed by NICE and also a wider decision problem of selecting
between multiple treatments.
When clinicians or other decision-makers decide which treat-
ments to recommend for a particular patient, a comparison
among all relevant treatment options is made. Clinical trials are
an important source of information for this selection process. If
no clinical trials exist that directly compare all relevant treatment
options, some form of indirect comparison based on the set of
available trial comparisons is unavoidable [2–5].
Indirect comparisons can be made by comparing the relative
effects of treatments against a common comparator or combining
a variety of comparisons that taken together form one or more
chains linking the treatments of interest (variously referred to as
a mixed or multiple treatment comparison or network meta-
analysis). Statistical methods of indirect comparison, in which
individual trials are weighted according to their precision, and
measures of overall uncertainty and consistency are available,
are in general preferable to more informal methods [6,7].
Indirect comparisons are not avoided by assuming that drugs
with similar pharmacological actions have a “class effect” (treat-
ing different drugs as having the same effectiveness). The accep-
tance that treatments exert a “class effect” is essentially an
indirect comparison with a strong assumption of identical effec-
tiveness [8]. And even where trials do exist that directly compare
relevant options, indirect evidence may still provide useful addi-
tional evidence and should be included [9,10]. Ades et al. pointed
out that “. . . to ignore indirect evidence either makes the unwar-
ranted claim that it is irrelevant, or breaks the established precept
of systematic review that synthesis should embrace all available
evidence” [11].
All forms of indirect comparison require some judgement
regarding the exchangeability between the effects of treatments
estimated from the various trials being combined. This assump-
tion of exchangeability is similar to an assumption of generaliz-
ability; indeed, if a set of historic trial results are regarded as
generalizable to a future patient population, this would imply
that they are exchangeable with each other.
It is important to consider the level at which exchangeability
is assumed; a network meta-analysis typically requires that the
relative treatment effects are considered exchangeable. As we are
only concerned about differences between trials that alter the
relative treatment effects rather than absolute levels of response
(factors that act as treatment effect modiﬁers), the assumption of
exchangeability is more likely to be satisﬁed.
In this article, we provide a practical example from NSCLC
showing that a network meta-analysis may help clinicians and
other decision-makers evaluate the available networks of trial
evidence and make informed treatment recommendations. The
case study presented shows the importance of considering all
informative evidence when comparing treatments [4,11,12]. This
may involve including trials with treatment arms that are not
relevant treatment options. We also demonstrate the importance
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of accounting for correlations in treatment effect estimates that
may arise from the connected nature of the trial data.
Methods
Identiﬁcation of Trials
We undertook a systematic review to identify randomized con-
trolled trials (RCTs) of the following treatments: erlotinib, doc-
etaxel, geﬁtinib, or pemetrexed, administered as second-line
therapy to stage III/IV NSCLC patients. These treatments are
currently licensed for the treatment of NSCLC in one or more
regulatory jurisdictions. The search was conducted within three
electronic databases: EMBASE; MEDLINE; and MEDLINE “in
process.” Searches were limited to English language publications
pertaining to human subjects published since January 1, 1997.
Searches were conducted on October 24, 2007. Full search
syntax is available from the authors.
Abstracts were initially reviewed by two reviewers according
to the following inclusion criteria:
1. study design: RCT;
2. patient population: NSCLC patients where at least some
proportion of patients have stage III/IV disease. Patients
were required to have received previous chemotherapy;
3. intervention: trials including one or more of the follow-
ing treatments used at their licensed dosages: docetaxel
(75 mg/m2 every 21 days), erlotinib (150 mg per day), geﬁ-
tinib (250 mg per day), pemetrexed (500 mg/m2 every 21
days). Trials including concomitant radiotherapy were
excluded;
4. reported end points: included hazard ratios for overall
survival.
Trials that did not directly compare or inform an indirect com-
parison of the speciﬁed treatments were excluded from the
network.
Full text articles were obtained for those abstracts that poten-
tially met these criteria and reviewed for ﬁnal inclusion. In addi-
tion, the reference lists of the included publications were checked
for potentially relevant trials and a search of presentations made
at recent oncology conferences was conducted to identify cur-
rently unpublished studies [13–15]. Quality assessment of each
trial was performed using the Jadad scale [16].
Statistical Analysis
Hazard ratios were selected as the preferred statistic for data
synthesis, as unlike binary data, this summary effect measure
accounts for censoring and incorporates time to event informa-
tion.
The network meta-analysis was based on the assumption that
the estimated log-hazard ratios (LHRs) comparing treatments
are exchangeable between trials and that we can add and sub-
tract estimates of the LHR to obtain indirect estimates of treat-
ment effects, e.g., LHRAB = LHRAC - LHRBC.
Estimates of the mean and standard error for the LHR for
each trial were required for the analysis. Where the mean and
95% conﬁdence interval (CI) for the hazard ratio were reported,
the mean LHR was estimated as:
LHR
HR HRuci lci
=
+ln( ) ln( )
2
(1)
and the standard error of the mean log hazard ratio as:
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Where the mean hazard ratio and a P-value were reported,
the mean log hazard ratio was estimated as:
LHR HR= ln( ) (3)
and the standard error of the mean log hazard ratio as:
s
HR
P
=
−
−
ln( )
( )Φ 1 1 2
(4)
whereF-1 is the inverse of the cumulative distribution function of
the normal distribution.
The relative treatment effects observed within the trials were
synthesized using a Bayesian hierarchical model. The model has
a regression structure with the predicted LHR for a study com-
paring treatments r and s equal to the difference between two
treatment coefﬁcients br and bs.
LHRr s r s, = −β β (5)
The coefﬁcient for placebo is set to zero so that the effect esti-
mates for active treatments are relative to placebo. Trial-speciﬁc
log hazard ratios (estimated from hazard ratios extracted from
the individual trials) are included in the model using a normal
likelihood function:
LHR N sr s r s, ,∼ β β−( )2 (6)
The meta-analysis was conducted using WinBUGS 1.4 (Medical
Research Council Biostatistics Unit, Cambridge, UK) [17]. The
model was run for a burnin period of 10,000 simulations and the
parameter nodes were monitored for a further 100,000 simula-
tions. The autocorrelation plots showed limited autocorrelation
and the BGR plots [18] showed that the model had converged
satisfactorily. The WinBUGS code is provided as an online
appendix.
Results
Identiﬁcation of Trials
The search of the published literature identiﬁed 1625 abstracts
that were reviewed. Seven full-text articles were obtained and ﬁve
relevant studies were identiﬁed that met the inclusion criteria:
SIGN [19]; JMEI [20]; TAX 317 [21]; BR21 [22]; and ISEL [23].
The two excluded publications [24,25] did not report original
trial results.
The review of conference presentations identiﬁed two further
potentially relevant studies: the Japanese V-15-32 trial presented
at American Society of Clinical Oncology [26] and the INTER-
EST trial presented at both the European Cancer Conference and
the World Conference on Lung Cancer [27]. After the reviews of
the full presentations, the INTEREST study was included and
V-15-32 was excluded as patients allocated to the docetaxel arm
received treatment at a lower dose currently licensed in Japan. An
additional trial, TITAN, comparing erlotinib with docetaxel or
pemetrexed was referred to in a discussion article presented at
the World Conference on Lung Cancer [28]; however, as this trial
has not been completed yet no data were available for inclusion
in the analysis.
Thus six studies were included in the network meta-analysis,
all were randomized international trials. The study and patient
characteristics are presented in Tables 1 and 2.
The six trials included a total of 4672 patients in their sur-
vival analyses; the smallest trial was TAX 317 [21] with 104
patients included and the largest was the ISEL study with 1692
patients [23].
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The median ages (57–63 years) and proportion of female
patients (25–36%) were similar across studies. Although the
majority of patients included in the analysis had received only
one previous course of chemotherapy, a notable number had
received more. In the ISEL [23] and BR21 [22] studies around
half of the patients had received more than one previous course
of treatment; in the remaining studies the proportion was con-
siderably less. The performance status of patients was similar
across studies with the majority of patients being Eastern Coop-
erative Oncology Group status 1 or 2.
The relatively low Jadad scores can partly be attributed to
three of the trials using an open-label design [19,20,27]. The low
score attained by INTEREST [27] is in part because of the limited
information available from the conference presentation.
In the opinion of the authors, there were no studies that
clearly should have been excluded from the analysis because of
differences in baseline characteristics. However, a sensitivity
analysis excluding the INTEREST study was conducted given
that this study was only reported as a conference presentation.
The reported hazard ratios and derived log hazard ratios
for each trial are shown in Table 3. A hazard ratio less than 1
indicates that a treatment reduces the mortality rate and
increases survival compared with the study comparator.
The network of evidence formed by these trials is shown in
Figure 1. The limited evidence network formed when we con-
sider only the evidence from the two trials including docetaxel,
erlotinib, and placebo, and the extended network formed when
we incorporate all identiﬁed trials are labelled.
Evidence Synthesis
The estimated hazard ratios for each treatment relative to
placebo from the analysis of all the identiﬁed trials are shown in
Figure 2. The estimated hazard ratio for docetaxel is 0.85 with a
CI of 0.72 to 1.00. This is higher than that of erlotinib (0.71;
0.58–0.85). The estimated hazard ratio for erlotinib compared to
docetaxel is 0.83 with a CI of 0.65 to 1.06 suggesting that
erlotinib may be associated with better outcomes. In addition,
this analysis also provides estimated hazard ratios for pemetr-
exed (0.85; 0.65–1.08) and geﬁtinib (0.88; 0.78–0.99) relative to
placebo.
The hazard ratios estimated from analysis of the limited
network are also shown in Figure 2. Analysis of this network
provides a mean hazard ratio and 95% CI for docetaxel and
erlotinib compared with placebo. The estimated hazard ratio for
docetaxel (0.51; 0.24–0.96) in this analysis is lower than that of
erlotinib (0.71; 0.58–0.85). The estimated hazard ratio for erlo-
tinib compared with docetaxel is 1.55 with a CI of 0.72 to 2.97,
suggesting that docetaxel may be associatedwith better outcomes.
Figure 3 shows the results of available direct pair-wise com-
parisons in the included trials compared with the results of
network meta-analysis for each comparison. For the comparison
of geﬁtinib and docetaxel for which two trials were available
(INTEREST, SIGN) the results of a standard pair-wise meta-
analysis are also presented. The network meta-analysis results
show a high level of agreement with the direct trial evidence. The
docetaxel versus placebo comparison is the only case where the
Table 1 Study characteristics of included trials
Author and date Trial name Trial design
Jadad
score Treatment
Number
randomized
Mean treatment
duration (months)
Shepherd 2005 BR21 Double-blind 3 Erlotinib 488 Not stated
Placebo 243 —
Hanna 2004 JMEI Open-label 2 Pemetrexed 283 4
Docetaxel 288 4
Shepherd 2000 TAX 317 Not stated 2 Docetaxel 55 4
Placebo 49 —
Thatcher 2005 ISEL Double blind 4 Geﬁtinib 1129 2.9
Placebo 563 2.7
Douillard 2007 (conference presentation) INTEREST Open-label 1 Geﬁtinib 723 4.4
Docetaxel 710 3.0
Cufer 2006 SIGN Open-label 2 Geﬁtinib 68 3.0
Docetaxel 73 2.8
Table 2 Patient characteristics for included trials
Trial Treatment Median age (years)
Percentage
female (%) Disease stage
Performance status (ECOG), % Number of previous
lines of chemotherapy0 1 2 3
BR21 Erlotinib 62 (range 34–87) 36 IIIB/IV 13.1 52.5 25.8 8.6 1; 51%:2; 50%
Placebo 59 (range 32–89) 34 IIIB/IV 14 54.3 23 8.6 1; 50%:2; 50%
JMEI Pemetrexed 59 (range 22–81) 31 IV; 75% 0 88.6 11.4 0 1
Docetaxel 57 (range 28–87) 25 IV; 75% 0 87.6 12.4 0 1
TAX317 Docetaxel 61 (range 37–73) 36 IIIA/B; 27%: IV; 73% 23.6 50.9 25.5 0 1; 80%: 2; 13%:3; 7%
Placebo 61 (range 28–77) 35 IIIA/B; 9%: IV; 81% 22.0 53.0 25.0 0 1; 76%: 2; 5%:3; 9%
ISEL Geﬁtinib 62 (range 28–90) 33 Locally advanced or metastatic 12 53 29 5* 1; 49%: 2; 50%:3; 1%
Placebo 61 (range 21–87) 33 Locally advanced or metastatic 12 56 26 5* 1; 49%: 2; 50%:3; 1%
INTEREST Geﬁtinib 61% <65 years 36 Locally advanced or metastatic 30 58 12 0 1; 84%: 2; 16%
Docetaxel 67% <65 years 33 Locally advanced or metastatic 25 63 12 0 1; 83%: 2;17%
SIGN Geﬁtinib 63 (range 34–85) 31 IIB/IV, 60% metastatic 19.1 44.1 36.8 0 1; 97%
Docetaxel 59.5 (range 29–83) 30 IIB/IV, 56% metastatic 15.1 56.2 28.8 0 1; 99%
*3.
ECOG, Eastern Cooperative Oncology Group.
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results of the network meta-analysis appear to differ substantially
from the direct evidence, although in this case the point estimate
generated from the network meta-analysis still falls within the CI
for the TAX317 trial that compared the treatments directly.
The comparisons between the various treatments from the
network meta-analysis could be presented as a series of 10 sepa-
rate pair-wise comparisons, each with a mean estimate and CI.
However, these would be difﬁcult to interpret. Instead, the prob-
ability of each treatment being the most effective, second most
effective, and so on is shown in Figure 4. The numbers represent
the probability of each ranking with the area of the circles being
proportional to the probability. This analysis shows that erlotinib
has an estimated 85% probability of being the most effective
treatment with respect to overall survival. There is considerable
uncertainty as towhich of pemetrexed, docetaxel, and geﬁtinib are
the second, third, and fourthmost effective based on the estimated
hazard ratios. Overall there is an estimated 90% probability that
all of the active treatments are more effective than placebo.
Given the low Jadad score associated with the INTEREST
trial, a sensitivity analysis was conducted excluding this trial
from the extended network meta-analysis. Removing this trial
did not change the ranking of treatments based on mean hazard
ratios. The estimated hazard ratios and CIs for erlotinib versus
placebo, and geﬁtinib versus placebo were unchanged. The
hazard ratios for pemetrexed versus placebo (0.77; 0.48–1.16)
and docetaxel versus placebo (0.77; 0.50–1.12) decreased and
the uncertainty around these estimates was increased.
The estimates of treatment effect generated by the network
meta-analysis are not independent [29]. Figure 5 presents the
correlations between estimated hazard ratios for each treatment
compared with placebo. These correlations arise because of the
structure of the network of trial evidence. For example, the trials
directly comparing geﬁtinib with docetaxel cause a correlation
between the estimated hazard ratios for these treatments com-
pared with placebo (correlation coefﬁcient 0.73). In contrast, the
estimated treatment effect for erlotinib versus placebo is uncor-
related with any other treatment effects as there are no trial data
comparing erlotinib with any of the other active treatments.
Although allowing for this correlation impacts primarily
on the uncertainty around the treatment effect estimates, for
example, the 95% CI for the estimated hazard ratio comparing
geﬁtinib with docetaxel is 0.92 to 1.16 (mean 1.03) if correlation
is accounted for and 0.85 to 1.27 (mean 1.03) when correlation is
ignored, it may also have some effect on the point estimate itself.
Table 3 Hazard ratios from individual studies
Study Treatment Comparator
Hazard ratio,
mean (95% CI)
Log hazard ratio,
mean (SE)
BR21 Erlotinib Placebo 0.70 (0.58, 0.85) -0.35 (0.10)
JMEI Pemetrexed Docetaxel 0.99 (0.82, 1.2) -0.02 (0.10)
TAX 317 Docetaxel Placebo 0.484 (P = 0.039)* -0.72 (0.35)
ISEL Geﬁtinib Placebo 0.89 (0.79, 1.01) -0.11 (0.06)
INTEREST Geﬁtinib Docetaxel 1.02 (0.91, 1.15) 0.02 (0.06)
SIGN Geﬁtinib Docetaxel 0.97 (0.61, 1.52) -0.04 (0.23)
*A number of P-values are reported for TAX317. Our analysis is based on the value of 0.039 given for the intention-to-treat population.When using the P-value of 0.004 reported for the
multivariable survival regression similar results are given for the network meta-analysis.
CI, conﬁdence interval; SE, standard error.
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Figure 1 Network for second-line non–small-
cell lung cancer.
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Figure 2 Network meta-analysis results. CI, con-
ﬁdence interval; HR, hazard ratio.
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Figure 3 Comparison of direct trial data and
network meta-analysis results.CI, conﬁdence inter-
val; HR, hazard ratio.
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Conclusion
In the introduction, we discussed the need to compare treatments
based on indirect trial evidence when making clinical decisions.
In the rest of the article we present a network meta-analysis
comparison between erlotinib and docetaxel for the treatment of
NSCLC. A comparison of the results of the analysis based on a
limited network, including only trials of docetaxel and erlotinib
with a common comparator, with an analysis of a more extensive
network including all identiﬁed trials demonstrated the impor-
tance of considering all relevant data.
The results of the two analyses including different trial sets
produced conﬂicting conclusions. The analysis of the limited
network suggested that docetaxel is more effective than erlotinib,
whereas the analysis of the extended network suggested the
opposite. The key difference is the estimated treatment effect for
docetaxel compared with placebo as the estimated hazard ratio
for erlotinib is the same in both analyses (0.71; 0.58–0.85). In the
limited network the hazard ratio for docetaxel compared to
placebo is estimated as 0.51 (95% CI 0.24–0.96) based only
upon the TAX 317 trial. This is a small trial and its CI is
correspondingly wide. In the extended network, the hazard ratio
for docetaxel compared with placebo is estimated as 0.85 (95%
CI: 0.72–1.00). The change in the estimate in the extended analy-
sis is caused by the indirect trial evidence from SIGN and
INTEREST studies linking geﬁtinib to docetaxel and the ISEL
study linking geﬁtinib to placebo. In general, indirect data are
less inﬂuential than direct data. For example, for a set of studies
of the same precision, the CI around a treatment effect estimated
from an indirect comparison via a common comparator will be
1.414 times the size of the CI estimated via a direct comparison.
However, in this example the inclusion of these trials alters the
overall estimate as the SIGN, INTEREST, and ISEL trials are
much larger than the TAX 317 study.
Estimates of the correlation between the treatment effect
estimates generated by the network meta-analysis were also pre-
1 2 3 4 5
Erlotinib
Pemetrexed
Docetaxel
Gefitinib
Placebo
Treatment
Ranking
0.85 0.10 0.04 0.02 0.00
0.12 0.39 0.18 0.23 0.08
0.03 0.34 0.47 0.14 0.01
0.00 0.16 0.30 0.52 0.01
0.00 0.00 0.01 0.09 0.90
Least effectiveMost effective
Figure 4 Network meta-analysis results displayed as probability of treatment
occupying different rankings.
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sented. This showed the substantial correlation in network meta-
analysis outputs that is generated by the underlying data
structure. It is important to account for these correlations when
estimating relative treatment effects from a network meta-
analysis, as they can have signiﬁcant effects on the estimated CIs.
Because of the correlation in treatment effects, it is unsafe to
use the CIs around the mean treatment effect (vs. placebo) as the
basis for comparing active treatments. For example, if treatment
effect estimates are positively correlated, the difference in means
may be statistically signiﬁcant even though the CIs overlap. In
this article we have included a diagram that shows the probabil-
ity of each treatment being most effective, second most effective,
etc. This provides a useful summary of the ranking of treatments
and uncertainty around these rankings. It is useful to have esti-
mates for all rankings, rather than just the probability of each
treatment being most effective, as in some cases individual treat-
ments may be disqualiﬁed on the basis of cost or clinical con-
traindication. In addition, if two treatments have a similar
probability of being most effective, the diagram allows the
decision-maker to consider the probabilities of the other rank-
ings. The diagram also summarizes the probability that active
treatment is better than placebo. As an alternative, it would be
possible to generate a similar diagram showing the probability of
each treatment being more effective in each possible pair-wise
comparison. However, we believe that the ranking diagram is a
more useful aid to decision-makers.
The analysis presented depends on the underlying assumption
of exchangeability: that effect measures are additive on the
selected scale. Differences in study design and patient popula-
tions that modify the relative treatment effects may invalidate
this assumption and cause the results of indirect comparisons to
be biased. In this analysis potential sources of heterogeneity that
could invalidate this assumption include variation in previous
lines of chemotherapy received. Further work in the form of
regression analysis of both study and individual level data could
potentially allow such confounding factors to be both identiﬁed
and adjusted for [30].
Although our example supports the importance of widening
the scope of the network to include comparators other than those
of immediate interest it should be noted that the search burden of
including additional comparators may be considerable. It may
therefore be pertinent to trade-off the costs associated with
expanding the comparator set against the likely impact of more
distant indirect comparisons [31].
In summary, network meta-analysis provides a useful synthe-
sis of trial data for decision-makers, particularly when more
complex networks of evidence exist. The case study presented
shows the importance of considering all informative evidence
when comparing treatments. Our example found that extending
the network of trial evidence to include further indirect data
altered the conclusions of the analysis. Care should also be taken
to reﬂect correlations in treatment effect estimates generated by
network meta-analysis when presenting the results of such indi-
rect comparisons.
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